secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001645113-26-000023
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC
--------------------------------------------------------------------------------

- PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.
- Secondary endpoints: ORR 34.6% (95% CI 24.2%-46.2%), median OS 9.7 months (95% CI 7.9-12.7 months).
- TTFields therapy with atezolizumab and gem/nab-pac well-tolerated; safety consistent with prior studies.
- Novocure plans to present further PANOVA-4 data at a future scientific forum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000023/0001645113-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000023/nvcr-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer